Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism
The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
CONTEXT: Patients with hypertension have a high prevalence of concurrent metabolic abnormalities, including obesity, dyslipidemia, and hyperglycemia. Clustering of these cardiovascular risk factors, defined as metabolic syndrome, causes a more pronounced target organ damage. Aldosterone excess has been found to be associated with glucose disorders and may contribute to cardiovascular damage. OBJECTIVE: The aim of our study was to assess the prevalence and the characteristics of the metabolic syndrome in a group of patients with hypertension due to primary aldosteronism compared with patients with essential hypertension. METHODS: The National Cholesterol Education Program Adult Treatment Panel III definition of the metabolic syndrome was used. Eighty-five patients with primary aldosteronism and 381 patients with essential hypertension were studied. Most patients were not receiving antihypertensive therapy during the investigation. RESULTS: Blood glucose and systolic blood pressure were higher (P < 0.05 and P < 0.01, respectively) and duration of hypertension was longer (P < 0.05) in primary aldosteronism than in essential hypertension. The prevalence of metabolic syndrome was higher in primary aldosteronism than in essential hypertension (41.1% vs. 29.6%; P < 0.05). Distribution of single components of the metabolic syndrome other than hypertension showed a higher prevalence of hyperglycemia in primary aldosteronism than in essential hypertension (27.0% vs. 15.2%; P < 0.05). CONCLUSIONS: Our findings confirm a negative effect of aldosterone excess on glucose metabolism and suggest that the recently reported higher rates of cardiovascular events in primary aldosteronism than in essential hypertension might be due to increased prevalence of the metabolic syndrome in the former condition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Primary aldosteronism (PA) is associated with increased risk for dysglycemia.”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [6]
In the citing paper
“Higher plasma mineralocorticoid levels may be associated with IR (, ).”
From Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management (2017) · cites this paper as [166]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547
The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension
Kaplan, N. M. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.7.1514 · Cited by 1,516
Cited by
Items 101–200 of 376
Role of the Renin-Angiotensin System and Aldosterone on Cardiometabolic Syndrome
Stiefel, P., Vallejo‐Vaz, A. J., Morillo, J. S. G., & Villar, J. (2011) · International Journal of Hypertension · doi:10.4061/2011/685238 · Cited by 61
“[30] showed that patients with primary hyperaldosteronism had higher levels of plasma glucose and prevalence of cardiometabolic syndrome than those with essential hypertension.”
BackgroundThe multifaceted mineralocorticoid receptor
Gomez‐Sanchez, E., & Gomez‐Sanchez, C. E. (2014) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2014.tb00569.x · Cited by 55
“PA is associated with alterations in the HPA axis (157) and shares obesity-related cardiometabolic risk factors including insulin resistance and diabetes mellitus that are ameliorated with treatment (115,155,384).”
Primary Aldosteronism and Resistant Hypertension: A Pathophysiological Insight
Bioletto, F., Bollati, M., Lopez, C., Arata, S., Procopio, M., Ponzetto, F., Ghigo, E., Maccario, M., & Parasiliti‐Caprino, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094803 · Cited by 63
Primary Aldosteronism as a Risk Factor for Vertebral Fracture
Notsu, M., Yamauchi, M., Yamamoto, M., Nawata, K., & Sugimoto, T. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3206 · Cited by 55
“(%) of participants with multiple VFs 8 (14) 5 (9) 0.”
BackgroundChen, W., Li, F., He, C., Zhu, Y., & Tan, W. (2014) · Irish Journal of Medical Science · doi:10.1007/s11845-013-1007-x · Cited by 53
“Whereas, according to five available studies in EH group [2, 21, 23, 25, 27], the prevalence of AGM was 16.”
BackgroundMethodNonalcoholic Fatty Liver Disease in Primary Aldosteronism: A Pilot Study
Fallo, F., Pozza, A. D., Tecchio, M., Tona, F., Sonino, N., Ermani, M., Catena, C., Bertello, C., Mulatero, P., Sabato, N., et al. (2009) · American Journal of Hypertension · doi:10.1038/ajh.2009.206 · Cited by 55
Self-citationARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions
Mulatero, P., Schiavi, F., Williams, T. A., Monticone, S., Barbon, G., Opocher, G., & Fallo, F. (2015) · Journal of Human Hypertension · doi:10.1038/jhh.2015.98 · Cited by 55
Self-citationBoscaro, M., Giacchetti, G., & Ronconi, V. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06597.x · Cited by 56
Understanding primary aldosteronism: impact of next generation sequencing and expression profiling
Monticone, S., Else, T., Mulatero, P., Williams, T. A., & Rainey, W. E. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.09.015 · Cited by 51
“, 2006), resulting in a higher rate of cardio- and cerebrovascular events, target organ damage, and metabolic syndrome in PA patients compared with essential hypertension with similar blood pressure and risk profiles (Fallo et al., 2006; Milliez et al., 2005; Mulatero et al., 2013a; Savard et al., 2013).”
Self-citationThe Association of Aldosterone With Obesity-Related Hypertension and the Metabolic Syndrome
Vogt, B., Bochud, M., & Burnier, M. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.07.009 · Cited by 54
Chen, Y., Lin, Y.-H., Huang, W., Chueh, E., Chen, L., Yang, S., Lin, P., Lin, L., Lin, Y., Wu, V., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00019 · Cited by 49
Approach to the Patient with Primary Aldosteronism: Utility and Limitations of Adrenal Vein Sampling
Turcu, A. F., & Auchus, R. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa952 · Cited by 51
Cardiovascular risk in primary aldosteronism: A systematic review and meta-analysis
Wu, X., Yu, J., & Tian, H. (2019) · Medicine · doi:10.1097/md.0000000000015985 · Cited by 53
Ndisang, J. F., & Jadhav, A. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.91000.2008 · Cited by 46
“In the recent National Cholesterol Education Program Adult Treatment Panel III study, it was reported that the prevalence of metabolic syndrome and cardiovascular events was higher in patients with primary aldosteronism than those with essential hypertension (2, 17).”
BackgroundDifferential diagnosis of primary aldosteronism subtypes
Mulatero, P., Bertello, C., Verhovez, A., Rossato, D., Giraudo, G., Mengozzi, G., Limerutti, G., Avenatti, E., Tizzani, D., & Veglio, F. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0038-1 · Cited by 47
Self-citationNagase, M. (2010) · Clinical and Experimental Nephrology · doi:10.1007/s10157-010-0298-8 · Cited by 46
“[65] observed that patients with PA had higher incidence of metabolic syndrome than those with essential hypertension (41.”
BackgroundBarceló, A., Piérola, J., Esquinas, C., de la Peña, M., Arqué, M., Alonso‐Fernández, A., Bauçà, J. M., Robles, J., Martín, B. B., & Barbé, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084362 · Cited by 50
The Mineralocorticoid Receptor in Salt-Sensitive Hypertension and Renal Injury
Ayuzawa, N., & Fujita, T. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020071041 · Cited by 45
Predictors of successful outcome after adrenalectomy for primary aldosteronism
Wang, W., Hu, W., Zhang, X., Wang, B., Bin, C., & Huang, H. (2012) · International Surgery · doi:10.9738/cc140.1 · Cited by 43
“Hypertension is not only the main symptom in patients with PHA, but is also the most important factor for morbidity and reduced quality of life due to a higher rate of cardiovascular complications, target organ damage, and metabolic syndrome than essential hypertension.(4,5) Thus, the control of hypertension is the mo…”
BackgroundMANAGEMENT OF ENDOCRINE DISEASE: The role of surgical adrenalectomy in primary aldosteronism
Hundemer, G. L., & Vaidya, A. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0863 · Cited by 44
Trésallet, C., Salepçioglu, H., Godiris-Petit, G., Hoang, C., Girerd, X. J., & Ménégaux, F. (2010) · Surgery · doi:10.1016/j.surg.2009.11.020 · Cited by 43
Prevalence, diagnosis and outcomes of treatment for primary aldosteronism
Yang, Y., Reincke, M., & Williams, T. A. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101365 · Cited by 44
Ronconi, V., Turchi, F., Rilli, S., Di Mattia, D., Agostinelli, L., Boscaro, M., & Giacchetti, G. (2010) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.007 · Cited by 41
“In addition, a higher prevalence of glycemic abnormalities and Metabolic Syndrome (MS) has been demonstrated in patients with primary aldosteronism (PA) compared with essential hypertensives (EH) [5].”
BackgroundMurase, K., Nagaishi, R., Takenoshita, H., Nomiyama, T., Akehi, Y., & Yanase, T. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej13-0060 · Cited by 43
Type 2 diabetic patients with resistant hypertension should be screened for primary aldosteronism
Mukherjee, J. J., Khoo, C. M., Thai, A. C., Chionh, S. B., Pin, L., & Lee, K. (2009) · Diabetes and Vascular Disease Research · doi:10.1177/1479164109350556 · Cited by 42
“Clinical characteristics of the 13 patients with confirmed PA (table 1) There was no difference in age, BMI, duration of diabetes or hypertension, HbA 1C , and number of antihypertensive medications used between the patients with and without PA. Patients with PA had higher mean systolic and diastolic BP but lower mean…”
InfluentialAnalysis of Insulin Sensitivity in Adipose Tissue of Patients with Primary Aldosteronism
Urbanet, R., Pilon, C., Calcagno, A., Peschechera, A., Hubert, E.-L., Giacchetti, G., Gomez-Sanchez, C., Mulatero, P., Toffanin, M., Sonino, N., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0097 · Cited by 38
“Criteria for the diagnosis of primary aldosteronism due to APA were as previously described (1).”
MethodSelf-citationCurrent pattern of primary aldosteronism diagnosis: Delayed and complicated
Lim, Y. Y., Shen, J., Fuller, P. J., & Yang, J. (2018) · Australian Journal of General Practice · doi:10.31128/ajgp-05-18-4587 · Cited by 38
The mineralocorticoid receptor—an emerging player in metabolic syndrome?
Thuzar, M., & Stowasser, M. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-020-00467-3 · Cited by 40
Gorini, S., Marzolla, V., Mammi, C., Armani, A., & Caprio, M. (2018) · Biomolecules · doi:10.3390/biom8030096 · Cited by 40
“A higher prevalence of metabolic syndrome and increased cardiovascular events have been observed in patients affected by primary aldosteronism, when compared to essential hypertension [39,105].”
BackgroundTurchi, F., Ronconi, V., di Tizio, V., Ceccoli, L., Boscaro, M., & Giacchetti, G. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.09.009 · Cited by 40
Freel, E. M., Tsorlalis, I. K., Lewsey, J., Latini, R., Maggioni, A. P., Solomon, S., Pitt, B., Connell, J., & McMurray, J. J. V. (2009) · Heart · doi:10.1136/hrt.2009.173344 · Cited by 36
“Indeed, the majority of clinical evidence supports an association between aldosterone excess and increased insulin resistance in hypertension, although there are conflicting reports as to whether this is a stronger”
BackgroundVascular Disturbances in Primary Aldosteronism: Clinical Evidence
Widimsky, J., Jr., Štrauch, B., Petrák, O., Rosa, J., Šomlóová, Z., Zelinka, T., & Holaj, R. (2012) · Kidney & Blood Pressure Research · doi:10.1159/000340031 · Cited by 36
Aldosterone Inhibition and Cardiovascular Protection: More Important Than it Once Appeared
Martínez, F. A. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6256-6 · Cited by 39
Genetics in endocrinology: Genetics of mineralocorticoid excess: an update for clinicians
Zennaro, M., Rickard, A. J., & Boulkroun, S. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0813 · Cited by 38
Goupil, R., Desbiens, L., Merabtine, A., Agharazii, M., Madore, F., Vaidya, A., Leung, A. A. C., Kline, G. A., Shaw, J. L. V., Ramsay, T., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.073507 · Cited by 36
Glucose Metabolism in Primary Aldosteronism
Remde, H., Hanslik, G., Rayes, N., & Quinkler, M. O. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1565208 · Cited by 33
Pathophysiology, Evaluation, and Medical Management of Adrenal Disorders
Kutikov, A., Crispen, P. L., & Uzzo, R. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00057-8 · Cited by 34
Surgery decreases the long-term incident stroke risk in patients with primary aldosteronism
Chang, Y.-H., Chung, S., Wu, C., Chueh, S., Chen, L., Lin, P., Lin, Y., Huang, K., Wu, V., & Chu, T. (2019) · Surgery · doi:10.1016/j.surg.2019.08.017 · Cited by 31
Russo, P., Lauria, F., Loguercio, M., Barba, G., Arnout, J., Cappuccio, F. P., Delorgeril, M., Donati, M. B., Iacoviello, L., Krogh, V., et al. (2007) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2006.07.012 · Cited by 30
“Alternatively, a direct effect of genetic variations at the CYP11B2 locus may influence aldosterone production and action, in turn affecting susceptibility to the metabolic syndrome, as recently suggested.(12,13) Notwithstanding which hypothesis is true, the biological plausibility of the association of 344C/T with th…”
BackgroundPossible Effect of Polycystic Ovary Syndrome (PCOS) on Cardiovascular Disease (CVD): An Update
Profili, N. I., Castelli, R., Gidaro, A., Manetti, R., Maioli, M., Petrillo, M., Capobianco, G., & Delitala, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030698 · Cited by 29
Nainani, A., Yang, J., Peters, S., & Russell, G. M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061671 · Cited by 29
Primary Aldosteronism and Obstructive Sleep Apnea: Casual Association or Pathophysiological Link?
Pecori, A., Buffolo, F., Pieroni, J., Forestiero, V., Sconfienza, E., Veglio, F., Mulatero, P., & Monticone, S. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1133-7255 · Cited by 30
“Higher prevalence of metabolic syndrome and diabetes has been shown in patients with PA compared with essential hypertension [83].”
BackgroundSelf-citationThe metabolic syndrome in primary aldosteronism
Fallo, F., Federspil, G., Veglio, F., & Mulatero, P. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0009-y · Cited by 30
Self-citationPrimary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment
Hundemer, G. L. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1185-x · Cited by 27
Huang, W., Chen, Y., Lin, Y., & Chueh, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.644260 · Cited by 30
“One of the potential causes is that the mineralocorticoid receptors, with high bonding affinity with both mineralocorticoids and glucocorticoids, were reported to be involved in the maturation of pre-adipocytes to adipocytes (34), which could be associated with the higher prevalence of hyperglycemia among PA patients…”
BackgroundSato, A., & Fukuda, S. (2009) · Journal of Human Hypertension · doi:10.1038/jhh.2009.81 · Cited by 29
Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure
Oginö, K., Kinugasa, Y., Kato, M., Yamamoto, K., Hisatome, I., Anker, S. D., & Doehner, W. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.12.039 · Cited by 27
Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas
Karagiannis, A. I., Τζιόμαλος, Κ., Kakafika, A. I., Athyros, V. G., Harsoulis, F., & Mikhailidis, D. P. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0094 · Cited by 28
Shariq, O. A., Fruth, K. M., Hanson, K. T., Cronin, P. A., Richards, M. L., Farley, D. R., Thompson, G. B., Habermann, E. B., & McKenzie, T. J. (2017) · Surgery · doi:10.1016/j.surg.2017.06.023 · Cited by 28
Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders
Garg, R., & Adler, G. K. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0567-8 · Cited by 27
Sato, A. (2015) · Hypertension Research · doi:10.1038/hr.2015.19 · Cited by 26
Byrd, J. B., & Brook, R. D. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2013.42 · Cited by 25
Quality of life in primary aldosteronism: A prospective observational study
Buffolo, F., Cavaglià, G., Burrello, J., Amongero, M., Tetti, M., Pecori, A., Sconfienza, E., Veglio, F., Mulatero, P., & Monticone, S. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13419 · Cited by 25
Self-citationHow common is primary aldosteronism?
Hundemer, G. L., Kline, G. A., & Leung, A. A. C. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000702 · Cited by 26
Colussi, G., Novello, M., Uzzau, A., Catena, C., & Sechi, L. A. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1565128 · Cited by 26
Berends, A. M. A., Buitenwerf, E., Gruppen, E. G., Sluiter, W. J., Bakker, S. J. L., Connelly, M. A., Kerstens, M. N., & Dullaart, R. P. F. (2018) · Clinical Endocrinology · doi:10.1111/cen.13891 · Cited by 26
Aldosterone and cardiovascular risk
Vogt, B., & Burnier, M. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0076-8 · Cited by 24
“Fallo et al. [ 39 ] found a signifi cantly higher prevalence of hyperglycemia in patients Aldosterone and Cardiovascular Risk I Vogt and Burnier I 453”
BackgroundTreating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome
Hayden, M. R., & Sowers, J. R. (2008) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2007.12.002 · Cited by 24
“The mechanism of action of aldosterone antagonists have been well defined over the years in regards to the myocardium, congestive heart failure and hypertension [168–172], and recently there has been increased interest regarding its effect in the CMS [174,175].”
BackgroundThe metabolic syndrome in primary aldosteronism
Fallo, F., Federspil, G., Veglio, F., & Mulatero, P. (2007) · Current Hypertension Reports · doi:10.1007/s11906-007-0019-1 · Cited by 24
Self-citationCardiovascular and metabolic characters of KCNJ5 somatic mutations in primary aldosteronism
Chang, Y., Lee, B., Chen, Z., Tsai, C., Chang, C., Liao, C., Pan, C., Peng, K., Chou, C., Lu, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1061704 · Cited by 24
“The prevalence of metabolic syndrome is also higher in PA patients compared to EH patients (25).”
ResultGenes implicated in insulin resistance are down-regulated in primary aldosteronism patients
Williams, T. A., Monticone, S., Urbanet, R., Bertello, C., Giraudo, G., Vettor, R., Fallo, F., Veglio, F., & Mulatero, P. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.02.007 · Cited by 25
Self-citationAldosterone directly affects apelin expression and secretion in adipocytes
Jiang, H., Ye, X.-P., Yang, Z., Zhan, M., Wang, H., Cao, H.-M., Xie, H.-J., Pan, C., Song, H., & Zhao, S. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0025 · Cited by 24
“Emerging evidence has shifted the focus to the crucial role of excess Ald in the pathogenesis of cardiovascular events and metabolic syndrome (MS) (Fallo et al. 2006).”
BackgroundVecchiola, A., Fuentes, C., Barros, E., Martínez‐Aguayo, A., García, H., Allende, F. A., Solari, S., Olmos, R. I., Carvajal, C. A., Tapia-Castillo, A., et al. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz023 · Cited by 23
Screening for primary aldosteronism
Schirpenbach, C., & Reincke, M. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.07.007 · Cited by 29
Aldosterone in gynecology and its involvement on the risk of hypertension in pregnancy
Sabbadin, C., Andrisani, A., Ambrosini, G., Bordin, L., Donà, G., Manso, J., Ceccato, F., Scaroni, C., & Armanini, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00575 · Cited by 22
“As previously reported, Aldo plays a key role as pro-inflammatory hormone and cardiovascular and metabolic risk factor (12, 13) and could play a certain role in the development of many Aldo-related disorders even in PCOS, such as hypertension, PE, metabolic alterations, Hashimoto’s thyroiditis and cardiovascular disea…”
BackgroundAdipose cell–adrenal interactions: current knowledge and future perspectives
Ronconi, V., Turchi, F., Bujalska, I. J., Giacchetti, G., & Boscaro, M. (2008) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2008.01.004 · Cited by 25
MECHANISMS IN ENDOCRINOLOGY: Brown adipose tissue in humans: regulation and metabolic significance
Thuzar, M., & Ho, K. K. Y. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1217 · Cited by 23
Turchi, F., Ronconi, V., di Tizio, V., Boscaro, M., & Giacchetti, G. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2011.144 · Cited by 25
Grasso, M., Boscaro, M., Scaroni, C. M., & Ceccato, F. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0288-6 · Cited by 25
Wannachalee, T., Caoili, E. M., Nanba, K., Nanba, A. T., Rainey, W. E., Shields, J. J., & Turcu, A. F. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa482 · Cited by 24
Spyroglou, A., Handgriff, L., Müller, L., Schwarzlmueller, P., Parasiliti‐Caprino, M., Fuß, C. T., Remde, H., Hirsch, A., O’Toole, S. M., Thuzar, M., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0040 · Cited by 23
Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome
Valaiyapathi, B., & Calhoun, D. A. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0819-5 · Cited by 23
Johnson, T. A., Fettweis, G., Wagh, K., Ceacero‐Heras, D., Krishnamurthy, M., de Medina, F. S., Martínez‐Augustin, O., Upadhyaya, A., Hager, G. L., & de la Rosa, D. Á. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413737121 · Cited by 22
Aldosterone aggravates glucose intolerance induced by high fructose
Sherajee, S. J., Rafiq, K., Nakano, D., Mori, H., Kobara, H., Hitomi, H., Fujisawa, Y., Kobori, H., Masaki, T., & Nishiyama, A. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.10.051 · Cited by 22
“Previous studies also showed that aldosterone excess in primary aldosteronism is related to impaired glucose homeostasis (Fallo et al., 2012, 2006) as well as insulin resistance (Catena et al., 2006; Stas et al., 2008).”
Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism
Grewal, S., Fosam, A., Chalk, L., Deven, A., Suzuki, M., Correa, R. R., Blau, J. E., Demidowich, A. P., Stratakis, C. A., & Muniyappa, R. (2021) · Endocrine · doi:10.1007/s12020-020-02576-y · Cited by 20
Wu, M.-H., Liu, F.-H., Lin, K.-J., Sun, J.-H., & Chen, S.-T. (2019) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000987 · Cited by 20
Lefranc, C., Friederich‐Persson, M., Foufelle, F., Cat, A. N. D., & Jaisser, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062881 · Cited by 22
“The prevalence of hyperaldosteronemia is increased in patients with MetS and vice versa [5,6,41].”
BackgroundManosroi, W., Phudphong, P., Atthakomol, P., & Phimphilai, M. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01135-y · Cited by 21
“In one study, statins were withdrawn for 4 weeks prior to lipid profile evaluation [47], while five studies stated that statins were continued during the study [12, 30, 33, 40, 51].”
BackgroundManagement of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment
Giacchetti, G., Turchi, F., Boscaro, M., & Ronconi, V. (2009) · Current Vascular Pharmacology · doi:10.2174/157016109787455716 · Cited by 24
Incidental Congestive Heart Failure in Patients With Aldosterone‐Producing Adenomas
Huang, W., Chen, Y., Lin, Y., Chen, L., Lin, P., Lin, Y., Liu, Y., Wu, C., Chueh, S., Chu, T., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012410 · Cited by 21
Liu, Y., Zhou, L., Liu, Z., Ma, Y., Lin, L., Zhu, Y., Wang, K., & Li, H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00023 · Cited by 28
Non-Alcoholic Fatty Liver Disease and Hypokalemia in Primary Aldosteronism Among Chinese Population
Chen, Y., Chen, X., Chen, Q., & Yu, C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.565714 · Cited by 21
“insulin resistance early on that was not found in later studies (18, 23).”
BackgroundMethodAdipocyte Mineralocorticoid Receptor
Infante, M., Armani, A., Marzolla, V., Fabbri, A., & Caprio, M. (2018) · Vitamins and hormones · doi:10.1016/bs.vh.2018.10.005 · Cited by 21
Loh, H. H., & Sukor, N. (2019) · Journal of Human Hypertension · doi:10.1038/s41371-019-0294-8 · Cited by 21
Effects of Primary Aldosteronism and Different Therapeutic Modalities on Glucose Metabolism
Kwak, M. K., Lee, J. Y., Kim, B., Lee, S. H., & Koh, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122194 · Cited by 20
“PA patients (N = 286) had higher systolic BP (SBP), diastolic BP (DBP), and prevalence of HTN than their matched controls (N = 816), but lower serum potassium concentrations.”
BackgroundInfluentialBenefits of Surgical Over Medical Treatment for Unilateral Primary Aldosteronism
Ahmed, S., & Hundemer, G. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.861581 · Cited by 22
“PA is associated with a higher risk of both diabetes mellitus (2, 22, 27–36) as well as metabolic syndrome (27, 29, 37) compared with essential hypertension.”
BackgroundHigh body fat percentage is associated with primary aldosteronism: a cross-sectional study
Manosroi, W., & Atthakomol, P. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00654-w · Cited by 18
Treatment of Unilateral PA by Adrenalectomy: Potential Reasons for Incomplete Biochemical Cure
Yang, Y., Reincke, M., & Williams, T. A. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0662-6081 · Cited by 19
Jadhav, A., & Ndisang, J. F. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.529 · Cited by 19
Aldosterone and type 2 diabetes mellitus
Zavatta, G., Casadio, E., Rinaldi, E., Pagotto, U., Pasquali, R., & Vicennati, V. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0065 · Cited by 18
“On the contrary, the relationship between aldosterone and insulin sensitivity has been studied for only a decade, since when PA was hypothesized to be linked to metabolic syndrome [37].”
BackgroundResultInfluentialEvaluation of Cortisol Production in Aldosterone-Producing Adenoma
Inoue, K., Yamazaki, Y., Tsurutani, Y., Suematsu, S., Sugisawa, C., Saito, J., Omura, M., Sasano, H., & Nishikawa, T. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-119878 · Cited by 19
Okazaki‐Hada, M., Moriya, A., Nagao, M., Oikawa, S., Fukuda, I., & Sugihara, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13312 · Cited by 20
Ruiz-Sánchez, J. G., Paja-Fano, M., Boillos, M. G., Peris, B. P., Corrales, E. P., Cano, A. M. G., Ramírez, P. A. P., Rojas‐Marcos, P. M., Delgado, A. V., Hoyos, E. G., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad400 · Cited by 18
The mineralocorticoid receptor forms higher order oligomers upon DNA binding
Fettweis, G., Johnson, T. A., Almeida‐Prieto, B., Weller‐Pérez, J., Presman, D. M., Hager, G. L., & de la Rosa, D. Á. (2024) · Protein Science · doi:10.1002/pro.4890 · Cited by 18
“Inappropriate activation of MR may mimic or counteract GR actions, promoting obesity and metabolic syndrome (Fallo et al., 2006; Schreier et al., 2022), enhancing inflammation and tissue fibrosis (van der Heijden et al., 2022) or diminishing it (Bigas et al., 2018) in a tissue-specific fashion…”
Changes in Body Mass Index in Pheochromocytoma Patients Following Adrenalectomy
Spyroglou, A., Adolf, C., Hahner, S., Quinkler, M. O., Ladurner, R., Reincke, M., & Beuschlein, F. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0042-124189 · Cited by 18
Er, L., Lin, M.-C., Tsai, Y., Hsiao, J., Yang, C.-Y., Chang, C., Peng, K., Chueh, S., & Wu, V. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001153 · Cited by 18
Lin, Y.-F., Peng, K., Chang, C., Hu, Y., Wu, V., Chung, S., & Taiwan Primary Aldosteronism Investigation (TAIPAI) Study Group (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.797 · Cited by 18
“[5] demonstrated that patients with PA had a significantly higher prevalence of metabolic syndrome (as defined by the Adult Treatment Panel III criteria) than those with essential hypertension.”
BackgroundResultKnuchel, R., Erlic, Z., Gruber, S., Amar, L., Larsen, C. K., Gimenez‐Roqueplo, A., Mulatero, P., Tetti, M., Pecori, A., Pamporaki, C., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1370525 · Cited by 19
“Similarly, PA has a higher prevalence of metabolic syndrome compared to patients with PHT (10), as well as a higher prevalence of obesity and some lipid abnormalities (11).”
BackgroundSelf-citationPartial Adrenalectomy—Why Should it be Considered?
Madala, A., Daugherty, M. R., & Bratslavsky, G. (2015) · Urology Practice · doi:10.1016/j.urpr.2015.03.006 · Cited by 18
Inflammatory Markers in Primary Aldosteronism
Šomlóová, Z., Petrák, O., Rosa, J., Štrauch, B., Indra, T., Zelinka, T., Haluzík, M., Zikán, V., Holaj, R., & Widimsky, J., Jr. (2016) · Physiological Research · doi:10.33549/physiolres.932994 · Cited by 17
“There is an evidence of more frequent left ventricular hypertrophy (Rossi et al., 1996), stroke, atrial fibrillation, myocardial infarction (Milliez et al., 2005) and metabolic syndrome (Fallo et al., 2006) in patients with PA.”
Background
Metadata
- Authors
- Fallo, F., Veglio, F., Bertello, C., Sonino, N., Della Mea, P., Ermani, M., Rabbia, F., Federspil, G., & Mulatero, P.
- Affiliations
- University of Padua (IT)
- University of Turin (IT)
- Corresponding author
- Fallo, Francesco
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-02
- Volume
- 91
- Issue
- 2
- Pages
- 454-459
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2099583783
- Semantic Scholar
- 5b2795dc0ee3d66f4f0cf0367b9210dd5492663a
- Cited by
- 372
- References
- 61
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 12 · 2023: 16 · 2022: 14 · 2021: 16 · 2020: 22 · 2019: 26 · 2018: 23 · 2017: 23 · 2016: 18 · 2015: 17 · 2014: 17 · 2013: 22 · 2012: 23
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Università degli Studi di Padova
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, metabolic syndrome, essential hypertension, hyperglycemia, aldosterone excess, glucose metabolism, cardiovascular risk, dyslipidemia, obesity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Blood Glucose, Blood Pressure, Female, Humans, Hyperaldosteronism, Hypertension, Cholesterol, HDL, Male, Middle Aged, Prospective Studies, Triglycerides, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.